We're increasing our Eli Lilly price target after another beat-and-raise quarter

Eli Lilly raised its full-year guidance following quarterly results that exceeded analyst expectations. The company's GLP-1 drug revenue contributed significantly to the earnings beat. An analyst or investment firm increased its price target for Eli Lilly stock following the announcement.

Next story